Evaluating Ultrasound and Abdominal CTMRI to Diagnose and Predict Sarcopenia Outcomes in Lung Cancer Patients

What this Trial Is About

Researchers are evaluating a musculoskeletal cross-modal imaging system combining ultrasound with abdominal CTMRI to diagnose sarcopenia in patients with lung cancer. The study aims to assess how this system can predict prognosis and the effects of nutritional support during the perioperative period, as well as the long-term outcomes for these patients. Sarcopenia involves loss of muscle mass and function and is common in lung cancer, affecting recovery and survival. Participants scheduled for radical lung cancer surgery will undergo whole-body ultrasound scans focusing on muscle and fat, along with abdominal CTMRI scans. These imaging tests are used together to provide a more comprehensive and stable diagnosis of sarcopenia. The study compares lung cancer patients with and without sarcopenia to evaluate the imaging systems diagnostic and prognostic value. During the study, participants will be monitored for perioperative complications within 7 days after surgery and for survival over 2 years from the initial ultrasound exam. Researchers will collect imaging data and track outcomes related to nutritional support and long-term prognosis. The study involves hospitalized adults aged 40 to 100 years who have had a recent CTMRI and are compliant with examinations. The total participation timeline extends up to 2 years for outcome assessments.

Assessment System of Sarcopenia in Lung Cancer Patients